Kyntra Bio (NASDAQ:KYNB – Get Free Report) and Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.
Earnings & Valuation
This table compares Kyntra Bio and Biorestorative Therapies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kyntra Bio | $6.44 million | 3.75 | $183.45 million | $45.30 | 0.13 |
| Biorestorative Therapies | $360,000.00 | 7.25 | -$14.24 million | ($21.40) | -0.09 |
Profitability
This table compares Kyntra Bio and Biorestorative Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kyntra Bio | 2,199.13% | N/A | -47.27% |
| Biorestorative Therapies | -3,088.27% | -508.42% | -230.94% |
Insider & Institutional Ownership
72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Kyntra Bio and Biorestorative Therapies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kyntra Bio | 1 | 1 | 4 | 0 | 2.50 |
| Biorestorative Therapies | 1 | 1 | 0 | 0 | 1.50 |
Kyntra Bio currently has a consensus price target of $37.25, suggesting a potential upside of 525.00%. Given Kyntra Bio’s stronger consensus rating and higher probable upside, equities analysts plainly believe Kyntra Bio is more favorable than Biorestorative Therapies.
Risk and Volatility
Kyntra Bio has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Biorestorative Therapies has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
Summary
Kyntra Bio beats Biorestorative Therapies on 12 of the 14 factors compared between the two stocks.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
About Biorestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
